References
- Anatelli F, Chuang ST, Yang XJ, Wang HL (2008). Value of Glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol, 130, 219-23. https://doi.org/10.1309/WMB5PX57Y4P8QCTY
- Abdelgawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM (2013). Can Glypican 3 be diagnostic for early hepatocellular carcinoma among egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9. https://doi.org/10.7314/APJCP.2013.14.12.7345
- Abouzied MM, Eltahir HM, Fawzy MA, et al (2015). Estimation of leucine aminopeptidase and 5-Nucleotidase increases alpha-fetoprotein sensitivity in human hepatocellular carcinoma cases. Asian Pac J Cancer Prev, 16, 959-63. https://doi.org/10.7314/APJCP.2015.16.3.959
- Bello BD, Rosa L, Campanini N, et al (2010). Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res, 16, 2157. https://doi.org/10.1158/1078-0432.CCR-09-1978
- Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 125, 89-97. https://doi.org/10.1016/S0016-5085(03)00689-9
- Christa L, Simon MT, Flinois JP, et al (1994). Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology, 106, 1312-20. https://doi.org/10.1016/0016-5085(94)90024-8
- Coston WM, Loera S, Lau SK, et al (2008). Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol, 32, 433-44. https://doi.org/10.1097/PAS.0b013e318158142f
- Di Tommaso L, Franchi G, Park YN, et al (2007). Diagnostic value of HSP70, Glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology, 45, 725-34. https://doi.org/10.1002/hep.21531
- Donato F, Tagger A, Gelatti U, et al (2002). Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol, 155, 323-31. https://doi.org/10.1093/aje/155.4.323
- Evason K, Grenert JP, Ferrell LD, Kakar S (2013). Immunohistochemical classification of hepatic adenomas and atypical hepatocellular neoplasms: correlation with clinicopathologic characteristics and chromosomal abnormalities. Mod Pathol, 44, 750-8.
- Hsu HC, Cheng W, Lai PL (1997). Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res, 57, 5179-84.
- Ismail S, Mayah W, Battia HE, et al (2015). Plasma nuclear factor kappa b and serum peroxiredoxin 3 in early diagnosis of hepatocellular carcinoma. Asian Pac J Cancer Prev, 16, 1657-66. https://doi.org/10.7314/APJCP.2015.16.4.1657
- Kandil DH, Cooper K (2009). Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 16, 125-9. https://doi.org/10.1097/PAP.0b013e3181992455
- Lagana SM, Moreira RK, Remotti HE, Bao F (2013). Glutamine synthetase, heat shock protein-70, and glypican-3 in intrahepatic cholangiocarcinoma and tumors metastatic to liver. Appl Immunohistochem Mol Morphol, 21, 254-7.
- Libbrecht L, Severi T, Cassiman D, et al (2006). Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol, 30, 1405-11. https://doi.org/10.1097/01.pas.0000213323.97294.9a
- Long J, Wang H, Lang ZW, et al (2011). Expression level of glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis and chronic hepatitis B. Hepatol Int, 5, 698-706. https://doi.org/10.1007/s12072-010-9230-2
- Pan Z, Chen C, Long H, et al (2013). Overexpression of gpc3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis. Mol Medicine Reports, 7, 969-974. https://doi.org/10.3892/mmr.2013.1279
- Rangaswami H, Bulbule A, Kundu GC (2006). Osteopontin: Role in cell signaling and cancer progression. Trends Cell Biol, 16, 79-87. https://doi.org/10.1016/j.tcb.2005.12.005
- Shafizadeh N, Ferrell LD, Kakar S (2008). Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol, 21, 1011-8. https://doi.org/10.1038/modpathol.2008.85
- Suzuki M, Sugimoto K, Tanaka J, et al (2010). Up-regulation of glypican-3 in human Hepatocellular carcinoma. Anti Cancer Res, 30, 5055-62.
- Tremosini S, Forner A, Boix L, et al (2012). Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut, 61, 1481-7. https://doi.org/10.1136/gutjnl-2011-301862
- Wang F, Jing X, Wang T, et al (2012). Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol, 137, 937-45. https://doi.org/10.1309/AJCP0KZZ5DSIGMNY
- Weng LL, Xiang JF, Lin JB, et al (2014). Asparagus polysaccharide and gum with hepatic artery embolization induces tumor growth and inhibits angiogenesis in an orthotopic hepatocellular carcinoma model. Asian Pac J Cancer Prev, 15, 10949-55.
- Yamauchi N, Watanabe A, Hishinuma M, et al (2005). The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathology, 18, 1591-8. https://doi.org/10.1038/modpathol.3800436
- Yan B, Wei JJ, Qian YM, et al (2011). Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. An Diagnostic Pathol, 15, 162-9. https://doi.org/10.1016/j.anndiagpath.2010.10.004
- Yip YC, Wang FH, Vong HT, Zhang M, Wen JM (2011). Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi, 40, 626-9.
- Zaakook M, Ayoub M, Abu Sinna E, El-Sheikh S (2013). Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology. J Egyptian Nat Cancer Inst, 25, 173-180. https://doi.org/10.1016/j.jnci.2013.07.004
- Zou ZQ, Ding YP, Long B, et al (2010). Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma. Hepatogastroenterology, 57, 102-3, 1285-90.
Cited by
- Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts 1H-NMR Spectroscopy vol.7, pp.4, 2017, https://doi.org/10.3390/metabo7040049
- mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans vol.10, pp.12, 2018, https://doi.org/10.3390/cancers10120465